Question 1

Who are the top researchers at Phio Pharmaceuticals (United States)?

Accepted Answer

Ranked on the quality score, Simon Paul Fricker, Benjamin Cuiffo and Pamela A. Pavco lead among researchers whose main affiliation is Phio Pharmaceuticals (United States).

Question 2

What are the most cited papers from Phio Pharmaceuticals (United States)?

Accepted Answer

The most cited paper from Phio Pharmaceuticals (United States) is "Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II–Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3" (Yong‐Chen Lu, Linda L. Parker, Tangying Lu et al., 2017), with 280 citations. Next come "Visualization of self-delivering hydrophobically modified siRNA cellular internalization" (133) and "Rabenosyn-5 defines the fate of the transferrin receptor following clathrin-mediated endocytosis" (93).

Question 3

Which research topics does Phio Pharmaceuticals (United States) publish most on?

Accepted Answer

By volume in 2022-now: CAR-T cell therapy research, Immunotherapy and Immune Responses, RNA Interference and Gene Delivery and Protein Degradation and Inhibitors.

Question 4

Which keywords describe research at Phio Pharmaceuticals (United States)?

Accepted Answer

By fractional works in 2022-now, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunotherapy, Tumor Regression, CAR T Cells, Chimeric Antigen Receptor, Gene Therapy, Innate Immunity and Dendritic Cells.

Question 5

Which fields of science does Phio Pharmaceuticals (United States) work in?

Accepted Answer

In 2022-now, 51% of research at Phio Pharmaceuticals (United States) is in Life Sciences, 45% in Health Sciences. Its largest fields are Medicine (45%), Biochemistry, Genetics and Molecular Biology (36%), Immunology and Microbiology (13%). It does 2.5× the world's share of Life Sciences.

Question 6

Is Phio Pharmaceuticals (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 54% higher than in 2018-2021.